All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.

Biological Description

Description: Trametinib is an ATP-noncompetitive inhibitor of MEK 1/2 (IC50s: 0.7/0.9 nM). It shows low inhibition for more than 180 kinases, including B-Raf, c-Raf, and MEK5.

Targets&IC50: MEK2:0.92 nM (cell free), MEK1:1.8 nM (cell free)

In vitro: Trametinib (JTP-74057) inhibited the phosphorylation of MBP regardless of the isotype of Raf and MEK (IC50s: 0.92 to 3.4 nM). JTP-74057 demonstrated no inhibition of the kinase activities of c-Raf, B-Raf, ERK1 and ERK2. HT-29 and COLO205 cells, which are known to have a constitutively active B-Raf mutant, were most sensitive to JTP-74057, showing subnanomolar IC50 values. The cell lines bearing a K-Ras mutation showed a wide range of sensitivity to JTP-74057. Among KRAS mutant cell lines, cell lines with an expression pattern suggestive of epithelial-to-mesenchymal transition were less sensitive to GSK1120212. A proportion of cell lines from certain tissue types not known to carry frequent RAF/RAS mutations also seemed to be sensitive to GSK1120212.

In vivo: Both 0.3 mg/kg and 1 mg/kg of JTP-74057 were effective in inhibiting the HT-29 xenograft growth, and 1 mg/kg of JTP-74057 blocked the tumor increase almost completely. Neither significant changes in body weight nor gross lesions at autopsy were observed in the mice treated with 1 mg/kg of JTP-74057. The phosphorylation of ERK1/2 was completely inhibited in the established tumor tissues by a single oral dose of 1 mg/kg JTP-74057, and both p15INK4b and p27KIP1 protein levels were upregulated after 14 days of treatment with JTP-74057. JTP-74057 blocked tumor necrosis factor-α and interleukin-6 production from PBMCs. AIA and CIA development were suppressed almost completely by 0.1 mg/kg of JTP-74057. In the CIA, JTP-74057 suppressed collagen-reactive T-cell proliferation ex vivo.

Kinase Assay: A Raf-MEK-ERK cascade kinase assay was carried out as previously described. Briefly, nonphosphorylated myelin basic protein (MBP) was coated onto an ELISA plate, and the active form of B-Raf/c-Raf was mixed with unphosphorylated MEK1/MEK2 and ERK2 in 10 μM ATP and 12.5 mM MgCl2 containing MOPS buffer in the presence of various concentrations of JTP-74057. The phosphorylation of MBP was detected by the anti-phosphoMBP antibody. Kinase inhibitory activities against a total of 99 kinases were tested by kinase profiler at 10 μM ATP.

Cell Research: These cells were maintained in media recommended by the providers. Exponentially growing cells were precultured in 96-well tissue culture plates for 24 h and then exposed to JTP-74057. Cell growth was determined by an in vitro toxicology assay kit, sulforhodamine B based. For combination studies, two compounds were simultaneously added to the HT-29 cells and incubated for 72 h. In the presence of various concentrations of compound A, the 50% inhibitory concentration (IC50) values of compound B were determined. Then, the fixed concentration of compound A versus the IC50 value of compound B was plotted. Conversely, the IC50 values of compound A were determined in the presence of various concentrations of compound B and plotted.

Animal Research: Female BALB/c-nu/nu mice were used. On day 0, HT-29 cells or COLO205 cells suspended in ice-cold HBSS (-) were inoculated subcutaneously into the right flank of the mice at 5x10^6 cells/100 μl/site or 1x10^6 cells/100 μl/site, respectively. The acetic acid-solvated form of JTP-74057 was dissolved in 10% Cremophor EL-10% PEG400 and was administered orally once daily for 14 days from the day when the mean tumor volume reached 100 mm^3. The tumor length [L (mm)] and width [W (mm)] were measured using a micro gauge twice a week after the commencement of dosing, and the tumor volume was calculated using the following formula: tumor volume (mm^3) = L x W x W/2. All procedures relating to the use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee of Japan Tobacco.

Chemical Properties

Molecular Weight: 615.404

Formula: C26H23FIN5O4

CAS No.: 871700-17-3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years

In solvent: -80°C for 2 years

Solubility Information

DMSO: 21 mg/mL (34.1 mM)

Ethanol: <1 mg/mL

( < 1 mg/ml refers to the product slightly soluble or insoluble )

Catalog #: T2125

Please email us at cs@medikonia.com for any enquiry. To place an order, please include the catalog number(s) of the product(s) in the email.

References and Literature

1. Yamaguchi T, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol, 2011, 39(1), 23-31.

2. Jing J, et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther. 2012 Mar;11(3):720-9.

3. Yamaguchi T, et al. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide. Inflamm Res, 2012, 61(5), 445-454.

4. KieΔling M K, Nicolay J P, Schlör T, et al. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib[J]. Oncotarget. 2017 Jul 11;8(28):45687-45697.

5. Klein C, Roussel G, Brun S, et al. 5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer’s disease[J]. Acta neuropathologica communications. 2018 Dec 11;6(1):136.

6. Wang X, Wu F, Wang H, et al. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation[J]. Journal of Experimental & Clinical Cancer Research. 2020, 39(1): 1-15.